Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China.
The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future acceptance in China, both firms said in a statement.
BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the spouses said last week they were expecting to win approval in the United States and Europe this season after trial results revealed the compound had a 95% efficacy rate and caused no serious side effects.